Tel Aviv shares ended Sunday lower on very thin trading of just NIS 591 million, as the global stock-market rally stalled on Friday. One of the stocks to buck the trend was smallcap biotech stock Biocancell, which jumped nearly 21% on turnover of NIS 8.1 million, more than 16 times its usual volume, after reporting it had successfully completed Phase IIb clinical trials for BC-819, a drug for treating superficial...